Evidence map›Paper›PMID 39147891›Full record

ArticleBone marrow transplantation2024

Comparing transplant outcomes in ALL patients after myeloablative conditioning in mismatch-related or unrelated donor settings.

Salman Otoukesh, Dongyun Yang, Sally Mokhtari, Hoda Pourhassan, Vaibhav Agrawal, Shukaib Arslan, Idoroenyi Amanam, Brian Ball, Paul Koller, Amandeep Salhotra and 16 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone marrow transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Salman OtoukeshDepartment of Hematologic Malignancies and Translational Science, City of Hope National Medical Center, Duarte, CA, USA.
Dongyun YangDepartment of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA, USA.
Sally MokhtariDepartment of Clinical and Translational Project Development, City of Hope National Medical Center, Duarte, CA, USA.
Hoda PourhassanDepartment of Hematologic Malignancies and Translational Science, City of Hope National Medical Center, Duarte, CA, USA.
Vaibhav AgrawalDepartment of Hematologic Malignancies and Translational Science, City of Hope National Medical Center, Duarte, CA, USA.
Shukaib ArslanDepartment of Hematologic Malignancies and Translational Science, City of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-8447-9607
Idoroenyi AmanamDepartment of Hematologic Malignancies and Translational Science, City of Hope National Medical Center, Duarte, CA, USA.
Brian BallDepartment of Hematologic Malignancies and Translational Science, City of Hope National Medical Center, Duarte, CA, USA.
Paul KollerDepartment of Hematologic Malignancies and Translational Science, City of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0003-3830-5320
Amandeep SalhotraDepartment of Hematologic Malignancies and Translational Science, City of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-9302-5041
Karamjeet SandhuDepartment of Hematologic Malignancies and Translational Science, City of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0001-8024-8484
Ahmed AribiDepartment of Hematologic Malignancies and Translational Science, City of Hope National Medical Center, Duarte, CA, USA.
Andrew ArtzDepartment of Hematologic Malignancies and Translational Science, City of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0003-0803-9607
Ibrahim AldossDepartment of Hematologic Malignancies and Translational Science, City of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0001-9564-4498
Vinod PullarkatDepartment of Hematologic Malignancies and Translational Science, City of Hope National Medical Center, Duarte, CA, USA.
Haris AliDepartment of Hematologic Malignancies and Translational Science, City of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-9728-7292
Amanda BlackmonDepartment of Hematologic Malignancies and Translational Science, City of Hope National Medical Center, Duarte, CA, USA.
Pamela BeckerDepartment of Hematologic Malignancies and Translational Science, City of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0001-6235-9463
Peter CurtinDepartment of Hematologic Malignancies and Translational Science, City of Hope National Medical Center, Duarte, CA, USA.
Forrest StewartDepartment of Hematologic Malignancies and Translational Science, City of Hope National Medical Center, Duarte, CA, USA.
Eileen SmithDepartment of Hematologic Malignancies and Translational Science, City of Hope National Medical Center, Duarte, CA, USA.
Anthony SteinDepartment of Hematologic Malignancies and Translational Science, City of Hope National Medical Center, Duarte, CA, USA.
Guido MarcucciDepartment of Hematologic Malignancies and Translational Science, City of Hope National Medical Center, Duarte, CA, USA.
Stephen J FormanDepartment of Hematologic Malignancies and Translational Science, City of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-2803-4152
Ryotaro NakamuraDepartment of Hematologic Malignancies and Translational Science, City of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-9082-0680
Monzr M Al MalkiDepartment of Hematologic Malignancies and Translational Science, City of Hope National Medical Center, Duarte, CA, USA. malmalki@coh.org.ORCID http://orcid.org/0000-0001-8226-471X

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3M
Division of Cancer Prevention, National Cancer Institute (NCI Division of Cancer Prevention) CA033572NCI NIH HHS P30 CA033572
6 · The paper itself

Abstract

The optimal myeloablative conditioning regimen for ALL patients undergoing hematopoietic cell transplant (HCT) with an alternative donor is unknown. We analyzed HCT outcomes ALL patients (n = 269) who underwent HCT at our center from 2010 to 2020 in complete remission (CR) after FTBI-etoposide and CNI-based GvHD prophylaxis for matched donor HCT (ETOP-package; n = 196) or FTBI-Fludarabine and post-transplant cyclophosphamide (PTCy)-based prophylaxis for HLA- mismatched (related or unrelated) donors (FLU-package; n = 64). Patients in FLU-package showed a significant delay in engraftment (p < 0.001) and lower cumulative incidence (CI) of any and extensive chronic GVHD (p = 0.009 and 0.001, respectively). At the median follow up of 4.6 years (range 1-12 years); non-relapse mortality, overall or leukemia-free survival and GVHD-free/relapse-free survival were not significantly impacted by the choice of conditioning. However, in patients at CR2 or with measurable residual disease (MRD+), there was a trend towards higher relapse after FLU-package (p = 0.08 and p = 0.07, respectively), while patients at CR1 regardless of MRD status had similar outcomes despite the package/donor type (p = 0.9 and 0.7, respectively). Our data suggests that FLU-package for alternative donors offers comparable outcomes to ETOP-package for matched donor HCT to treat ALL. Disease status and depth of remission at HCT were independent predictors for better outcomes.

Indexed as

Hematopoietic Stem Cell TransplantationTransplantation ConditioningUnrelated DonorsAdolescentAdultAgedChildChild, PreschoolFemaleGraft vs Host DiseaseHumansMaleMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaYoung Adult

Identifiers

PMID39147891
PMCPMC11530400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.